Cerebral venous sinus thrombosis as a complication of heparin-induced thrombocytopenia in myasthenia gravis: A rare and complex case

TL;DR

This paper presents a rare case where a myasthenia gravis patient developed cerebral venous sinus thrombosis due to heparin-induced thrombocytopenia, highlighting the need for careful monitoring.

Contribution

The paper reports a rare and complex case linking CVST, HIT, and MG, emphasizing the importance of early recognition and tailored treatment.

Findings

CVST occurred in a myasthenia gravis patient following heparin administration during plasma exchange therapy.

Discontinuation of heparin and initiation of fondaparinux led to effective anticoagulation and clinical improvement.

The case underscores the need for heightened awareness and proactive strategies in managing such complex scenarios.

Abstract

Cerebral venous sinus thrombosis (CVST) is an uncommon yet critical complication, especially when arising from heparin-induced thrombocytopenia (HIT). In patients with preexisting conditions such as myasthenia gravis (MG), this correlation adds further complexity to clinical management and outcomes.

We report a unique case of CVST induced by HIT in a patient with an established diagnosis of MG. Following plasma exchange therapy, which included heparin administration, the patient developed symptoms indicative of CVST. Diagnostic imaging confirmed thrombosis in the cerebral venous sinuses. Management involved the immediate discontinuation of heparin and the initiation of fondaparinux, leading to effective anticoagulation and clinical improvement.

This case illustrates the rare intersection of CVST and HIT within the context of MG, underscoring the potential risks associated with heparin therapy in vulnerable patient populations. Early recognition of the signs is essential, as these conditions, in combination, demand prompt and specialized interventions to prevent serious complications.

The successful management of this complex case demonstrates the importance of heightened awareness and proactive strategies in patients with MG undergoing heparin therapy. This report advocates for careful monitoring and tailored treatment to mitigate risks in similarly complex clinical scenarios.

Figures